Literature DB >> 31174946

A unidirectional porous beta-tricalcium phosphate material (Affinos®) for reconstruction of bony defects after excision of fibular bone for spinal surgery graft.

Hiroshi Noguchi1, Toru Funayama2, Masao Koda2, Yasushi Iijima3, Hiroshi Kumagai2, Tetsuhiro Ishikawa4, Atsuomi Aiba5, Tetsuya Abe2, Katsuya Nagashima2, Kousei Miura2, Shigeo Izawa2, Satoshi Maki6, Takeo Furuya6, Masashi Yamazaki2.   

Abstract

The aim of this study was to elucidate the bone regeneration-inducing capability of Affinos®, a newly developed, high-porosity unidirectional porous β-TCP artificial bone. We compared the ability of Affinos® and OSferion®, a commercially available β-TCP product, to induce bone regeneration following implantation into bony defects left after fibula harvesting for spinal fusion surgery. Study subjects underwent surgery to harvest non-vascularized fibula grafts for spinal fusion surgery and were implanted with either Affinos® (19 patients) or OSferion® (15 patients, control group) at the defect site. The minimal and mean follow up periods were 6 and 11 months after surgery, respectively. X-rays of the lower leg taken 1-2 weeks after surgery and at the final follow-up visit were used to evaluate fibular-β-TCP continuity and fibula defect filling ratio. There was no significant difference in radiographic continuity in the fibula between the two groups. The fibula defect filling ratio for the Affinos® group decreased from 0.94 ± 0.17 at 1-2 weeks to 0.77 ± 0.14 at 10 months. For the OSferion® control group, the fibula defect filling ratio decreased from 0.94 ± 0.14 at 1-2 weeks to 0.52 ± 0.27 at final follow-up. The Affinos® group showed a significantly higher fibula defect filling ratio compared to that for the OSferion® group (p = 0.003). These results indicate that Affinos® has slow absorption rates and significant defect filling activity compared with OSferion®. Thus, Affinos® could be a suitable substitute to fill bony defects induced by fibula harvesting for spinal reconstruction surgery.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone graft donor site; Bone remodeling; Regeneration of fibula; Spinal fusion surgery; β-tricalcium phosphate

Mesh:

Substances:

Year:  2019        PMID: 31174946     DOI: 10.1016/j.jocn.2019.05.021

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Biological and microbiological behavior of calcium aluminate cement-based blend for filling of bone defects.

Authors:  Luana Marotta Reis de Vasconcellos; Kaíke Lessa Camporês; Julia Marinzeck de Alcântara Abdala; Marilia Nanni Vieira; Ivone Regina de Oliveira
Journal:  J Mater Sci Mater Med       Date:  2019-12-23       Impact factor: 3.896

2.  A Novel Unidirectional Porous β-tricalcium Phosphate Bone Substitute in Orthopedic Surgery: A Technical Note and Case Illustrations.

Authors:  Toru Funayama; Hiroshi Noguchi; Hiroshi Kumagai; Tomokazu Yoshioka; Masashi Yamazaki
Journal:  Cureus       Date:  2020-03-30

3.  How much platelet-rich plasma can be soak-loaded onto beta-tricalcium phosphate? A comparison with or without a unidirectional porous structure.

Authors:  Norihito Arai; Tomokazu Yoshioka; Hisashi Sugaya; Akihiro Kanamori; Masashi Yamazaki
Journal:  J Rural Med       Date:  2021-01-05

Review 4.  Unidirectional porous beta-tricalcium phosphate and hydroxyapatite artificial bone: a review of experimental evaluations and clinical applications.

Authors:  Toru Funayama; Hiroshi Noguchi; Hiroshi Kumagai; Kosuke Sato; Tomokazu Yoshioka; Masashi Yamazaki
Journal:  J Artif Organs       Date:  2021-04-23       Impact factor: 1.731

5.  A clinical trial of a unidirectional porous tricalcium phosphate filling for defects after resection of benign bone lesions: a prospective multicenter study.

Authors:  Kunihiro Ikuta; Yoshihiro Nishida; Takehiro Ota; Satoshi Tsukushi; Eiji Kozawa; Hiroatsu Nakashima; Kenji Yamada; Satoshi Yamashita; Shiro Imagama
Journal:  Sci Rep       Date:  2022-09-26       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.